Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blonanserin - Sumitomo Pharma

Next Previous
X
Search
Drug Profile

Blonanserin - Sumitomo Pharma

Alternative Names: AD-5423; DSP-5423; DSP-5423P; Lonasen; LONASEN Tape

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Bukwang Pharmaceutical; Nitto Denko; Sumitomo Pharma
  • Class Antipsychotics; Piperazines; Piperidines
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 26 Sep 2022 No development reported - Preregistration for Schizophrenia (In children) in Japan (PO)
  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 31 Mar 2022 Dainippon Sumitomo Pharma completes a phase III trial in Schizophrenia (In adolescents) in Japan (PO) (JapicCTI-111725)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top